14:51:44 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-05-16 Extra Bolagsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-05-02 X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-08 X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-09 X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 Årsstämma 2022
2022-04-21 Bokslutskommuniké 2021
2021-09-30 Extra Bolagsstämma 2021
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-10 X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 Årsstämma 2021
2021-04-20 Bokslutskommuniké 2020
2020-06-26 Årsstämma 2020
2020-06-01 Bokslutskommuniké 2019
2019-02-07 Split LIFE 4:1
2018-12-11 Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2024-06-06 08:00:00

Bergen, Norway, June 6th, 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the company has concluded the sterilization protocol for production preparations, to be implemented in the automated sensor production.

The Lifecare organization is working on preparations for automated production after a successful pilot production at the end of Q1. Part of these preparations has also been to finalize a procedure for sterilizing the sensors, including both the advanced chemistry and sensitive electronics. In our early product development, we have applied Gamma radiation as sterilizing method, being costly and complex in a logistics perspective.

Lifecare has now concluded on a protocol for a sterilization based on exposing the implant for UV-light and Ozone. The method is gentle, timesaving and very cost-effective, compared to alternative sterilization methods.

- This method can easily be implemented in the production line and scaled up in an automated production. The method of combining UV-light and Ozone is well proven, cost efficient and only takes a few minutes, says CEO Joacim Holter at Lifecare.

Lifecare, in collaboration with the Norwegian University of Life Sciences (NMBU), has carried out trials and analysis, and can therefore document that the method meets the high standards necessary for our medical device. Finalizing the sterilization protocol has also been important in the preparations towards the planned longevity studies (veterinary), as the sensor with electronics will be fully implanted under the patient's skin. In both perspectives the implant must be sterile to not cause infection or irritation.

Lifecare's required specifications for sterilization has been clear all along for this important part of sensor production. In the sterilization process, Lifecare is dependent not to expose the sensor's advanced chemistry and electronics to damage. Therefore, we have spent a lot of resources over a period of time to conclude a method that satisfies the requirements for sterilization and is gentle enough for the sensor. We have tested various methods, and our investigations show that heat, pressure, gamma radiation, chemicals and gas cannot be used.